Total Payments
$977.88
2024 Payments
$193.88
Companies
17
Transactions
36
Medicare Patients
5,989
Medicare Billing
$663,913
Payment Breakdown by Category
Food & Beverage$821.32 (84.0%)
Education$156.56 (16.0%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $821.32 | 21 | 84.0% |
| Education | $156.56 | 7 | 16.0% |
| Unspecified | $0 | 8 | 0.0% |
Payments by Type
General
$977.88
28 transactions
Ownership
$0
8 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Taiho Oncology, Inc. | $158.67 | 2 | $0 (2019) |
| Janssen Biotech, Inc. | $105.34 | 2 | $0 (2023) |
| TESARO, Inc. | $99.99 | 1 | $0 (2018) |
| Genentech USA, Inc. | $76.89 | 3 | $0 (2024) |
| Ipsen Biopharmaceuticals, Inc | $75.00 | 1 | $0 (2017) |
| Daiichi Sankyo Inc. | $73.19 | 2 | $0 (2024) |
| PFIZER INC. | $70.41 | 4 | $0 (2024) |
| AVEO Pharmaceuticals, Inc. | $69.99 | 1 | $0 (2023) |
| Genmab U.S., Inc. | $65.17 | 2 | $0 (2024) |
| Lilly USA, LLC | $58.54 | 3 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $193.88 | 9 | Genmab U.S., Inc. ($65.17) |
| 2023 | $116.66 | 5 | AVEO Pharmaceuticals, Inc. ($69.99) |
| 2022 | $67.48 | 3 | Daiichi Sankyo Inc. ($43.99) |
| 2021 | $32.90 | 3 | Lilly USA, LLC ($20.98) |
| 2020 | $0 | 1 | Cornerstone Specialty Network LLC |
| 2019 | $187.52 | 7 | Janssen Biotech, Inc. ($81.91) |
| 2018 | $270.22 | 5 | Taiho Oncology, Inc. ($115.37) |
| 2017 | $109.22 | 3 | Ipsen Biopharmaceuticals, Inc ($75.00) |
All Payment Transactions
36 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 08/28/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $29.20 | General |
| Category: ONCOLOGY | ||||||
| 08/08/2024 | Janssen Pharmaceuticals, Inc | — | Education | In-kind items and services | $25.72 | General |
| 07/12/2024 | Genmab U.S., Inc. | Tivdak (Drug) | Food and Beverage | In-kind items and services | $18.49 | General |
| Category: Oncology | ||||||
| 05/28/2024 | Lilly USA, LLC | VERZENIO (Drug), RETEVMO, JAYPIRCA | Food and Beverage | In-kind items and services | $14.32 | General |
| Category: Oncology | ||||||
| 05/18/2024 | Genmab U.S., Inc. | Epkinly (Drug) | Food and Beverage | In-kind items and services | $46.68 | General |
| Category: Oncology | ||||||
| 05/15/2024 | Genentech USA, Inc. | Lunsumio (Biological) | Food and Beverage | In-kind items and services | $37.61 | General |
| Category: BioOncology | ||||||
| 04/17/2024 | PFIZER INC. | ELREXFIO (Drug), ADCETRIS | Food and Beverage | In-kind items and services | $21.86 | General |
| Category: ONCOLOGY | ||||||
| 2024 | Cornerstone Specialty Network LLC | — | — | — | $0.00 | Ownership |
| 2024 | Cornerstone Specialty Network LLC | — | — | — | $0.00 | Ownership |
| 10/25/2023 | Janssen Biotech, Inc. | TECVAYLI (Biological), DARZALEX | Food and Beverage | In-kind items and services | $23.43 | General |
| Category: Oncology | ||||||
| 02/02/2023 | AVEO Pharmaceuticals, Inc. | FOTIVDA (Drug) | Education | In-kind items and services | $69.99 | General |
| Category: Oncology | ||||||
| 01/24/2023 | Lilly USA, LLC | VERZENIO (Drug) | Food and Beverage | In-kind items and services | $23.24 | General |
| Category: Oncology | ||||||
| 2023 | Cornerstone Specialty Network LLC | — | — | — | $0.00 | Ownership |
| 2023 | Cornerstone Specialty Network LLC | — | — | — | $0.00 | Ownership |
| 06/29/2022 | Daiichi Sankyo Inc. | ENHERTU (Drug) | Food and Beverage | In-kind items and services | $43.99 | General |
| Category: ONCOLOGY | ||||||
| 05/16/2022 | PFIZER INC. | IBRANCE (Drug) | Food and Beverage | In-kind items and services | $23.49 | General |
| Category: ONCOLOGY | ||||||
| 2022 | Cornerstone Specialty Network LLC | — | — | — | $0.00 | Ownership |
| 09/16/2021 | Lilly USA, LLC | CYRAMZA (Drug), VERZENIO, RETEVMO | Food and Beverage | In-kind items and services | $20.98 | General |
| Category: Oncology | ||||||
| 06/01/2021 | Gilead Sciences, Inc. | — | Education | In-kind items and services | $11.92 | General |
| 2021 | Cornerstone Specialty Network LLC | — | — | — | $0.00 | Ownership |
| 2020 | Cornerstone Specialty Network LLC | — | — | — | $0.00 | Ownership |
| 12/17/2019 | Janssen Biotech, Inc. | DARZALEX (Biological) | Food and Beverage | In-kind items and services | $81.91 | General |
| Category: Oncology | ||||||
| 11/05/2019 | Genentech USA, Inc. | Perjeta (Biological), Kadcyla | Food and Beverage | In-kind items and services | $25.00 | General |
| Category: BioOncology | ||||||
| 08/15/2019 | Amgen Inc. | — | Education | In-kind items and services | $11.07 | General |
| 07/03/2019 | Genentech USA, Inc. | VENCLEXTA (Biological) | Food and Beverage | In-kind items and services | $14.28 | General |
| Category: BioOncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 34 | 1,487 | 22,580 | $468,565 | $157,885 |
| 2022 | 33 | 1,389 | 4,479 | $322,485 | $112,068 |
| 2021 | 33 | 1,441 | 7,007 | $440,056 | $183,350 |
| 2020 | 37 | 1,672 | 7,490 | $574,396 | $210,610 |
Total Patients
5,989
Total Services
41,556
Medicare Billing
$663,913
Procedure Codes
137
All Medicare Procedures & Services
137 procedure records from CMS Medicare Utilization — Page 1 of 6
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 11 | 1,860 | $61,380 | $34,462 | 56.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 147 | 361 | $66,424 | $32,977 | 49.6% |
| J1439 | Injection, ferric carboxymaltose, 1 mg | Office | 2023 | 11 | 15,750 | $43,313 | $13,741 | 31.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 137 | 191 | $23,875 | $10,749 | 45.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 47 | 81 | $20,088 | $10,661 | 53.1% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 20 | 110 | $38,500 | $10,461 | 27.2% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 207 | 715 | $25,025 | $5,420 | 21.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 34 | 34 | $12,036 | $5,180 | 43.0% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 161 | 467 | $27,086 | $4,823 | 17.8% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 50 | 99 | $13,860 | $4,445 | 32.1% |
| J1750 | Injection, iron dextran, 50 mg | Office | 2023 | 11 | 280 | $14,560 | $3,762 | 25.8% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 22 | 119 | $9,044 | $2,517 | 27.8% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 35 | 240 | $10,560 | $2,442 | 23.1% |
| 82728 | Ferritin (blood protein) level | Office | 2023 | 75 | 178 | $9,968 | $2,378 | 23.9% |
| 99195 | Drawing of blood for a medical problem | Office | 2023 | 12 | 40 | $6,480 | $2,245 | 34.6% |
| 83521 | Measurement of immunoglobulin light chains | Office | 2023 | 19 | 102 | $4,386 | $1,693 | 38.6% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 11 | 71 | $6,390 | $1,428 | 22.3% |
| J3489 | Injection, zoledronic acid, 1 mg | Office | 2023 | 23 | 178 | $35,600 | $1,055 | 3.0% |
| 83550 | Iron binding capacity | Office | 2023 | 60 | 104 | $3,432 | $891.28 | 26.0% |
| 82784 | Gammaglobulin (immune system protein) measurement | Office | 2023 | 36 | 95 | $3,800 | $856.34 | 22.5% |
| 83615 | Lactate dehydrogenase (enzyme) level | Office | 2023 | 65 | 144 | $4,320 | $852.48 | 19.7% |
| 96360 | Infusion into a vein for hydration, 31-60 minutes | Office | 2023 | 12 | 33 | $3,795 | $773.76 | 20.4% |
| 84165 | Protein measurement, serum | Office | 2023 | 38 | 66 | $3,960 | $684.45 | 17.3% |
| 83540 | Iron level | Office | 2023 | 60 | 104 | $2,600 | $659.36 | 25.4% |
| 82607 | Cyanocobalamin (vitamin b-12) level | Office | 2023 | 30 | 43 | $2,666 | $635.54 | 23.8% |
About Dr. Wayne Ormsby, M.D
Dr. Wayne Ormsby, M.D is a Medical Oncology healthcare provider based in Murray, Utah. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/21/2007. The National Provider Identifier (NPI) number assigned to this provider is 1851417158.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Wayne Ormsby, M.D has received a total of $977.88 in payments from pharmaceutical and medical device companies, with $193.88 received in 2024. These payments were reported across 36 transactions from 17 companies. The most common payment nature is "Food and Beverage" ($821.32).
As a Medicare-enrolled provider, Ormsby has provided services to 5,989 Medicare beneficiaries, totaling 41,556 services with total Medicare billing of $663,913. Data is available for 4 years (2020–2023), covering 137 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical Oncology
- Other Specialties Hematology & Oncology, Hematology
- Location Murray, UT
- Active Since 03/21/2007
- Last Updated 03/30/2017
- Taxonomy Code 207RX0202X
- Entity Type Individual
- NPI Number 1851417158
Products in Payments
- Lonsurf (Drug) $158.67
- ZEJULA (Drug) $99.99
- DARZALEX (Biological) $81.91
- Somatuline Depot 120mg-.5ml (Drug) $75.00
- FOTIVDA (Drug) $69.99
- IBRANCE (Drug) $48.55
- Epkinly (Drug) $46.68
- ENHERTU (Drug) $43.99
- Lunsumio (Biological) $37.61
- VERZENIO (Drug) $37.56
- Enhertu (Drug) $29.20
- Perjeta (Biological) $25.00
- Xofigo (Drug) $25.00
- TECVAYLI (Biological) $23.43
- ELREXFIO (Drug) $21.86
- Myrbetriq (Drug) $21.12
- CYRAMZA (Drug) $20.98
- Tivdak (Drug) $18.49
- AFINITOR (Drug) $17.06
- VENCLEXTA (Biological) $14.28
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.